425: XOMA Royalty to be Acquired by Ligand Pharmaceuticals

XOMA Royalty Corporation announced a definitive agreement to be acquired by Ligand Pharmaceuticals Incorporated in a merger transaction.

Summary

• XOMA Royalty Corporation has entered into a definitive agreement to be acquired by Ligand Pharmaceuticals Incorporated.
• The transaction involves a holding company reorganization followed by a merger where Ligand's subsidiary, Flex Merger Sub, Inc., will merge with XOMA Royalty Holdings Corporation.
• XOMA Royalty stockholders will receive $39.00 in cash per share, plus one contingent value right (CVR) per share.
• The CVR represents a contractual right to receive contingent cash payments derived from the net proceeds of a pending litigation against Janssen Biotech, Inc. (Janssen Litigation).
• The merger is subject to XOMA Royalty stockholder approval, regulatory approvals, and other customary closing conditions.
• The transaction is expected to be completed in the third quarter of 2026.
• XOMA Royalty stockholders are urged to read the proxy statement/prospectus carefully for detailed information, including risk factors.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a strategic acquisition at a premium valuation, although the contingent nature of the CVR introduces significant uncertainty.

Positives

• XOMA Royalty stockholders will receive $39.00 per share in cash, representing a significant premium over recent trading prices.
• The inclusion of a contingent value right (CVR) offers potential upside participation for XOMA Royalty stockholders from the outcome of the Janssen Litigation.
• The merger process involved multiple parties and rounds of bidding, suggesting the final offer is competitive.
• Ligand Pharmaceuticals has sufficient financing and no financing contingency for the transaction.
• The XOMA Royalty Board of Directors unanimously recommends that stockholders vote FOR the merger agreement and related proposals.

Negatives

• The CVRs are highly contingent and may have no value, as payments depend entirely on the outcome of the Janssen Litigation, which is at an early stage and highly uncertain.
• Any recovery from the Janssen Litigation will be net of significant litigation costs, taxes, and other expenses, potentially reducing the amount available for CVR holders.
• The CVRs are non-transferable except in limited circumstances and will not be listed or traded, limiting liquidity for this component of the merger consideration.
• XOMA Royalty stockholders will forego any future appreciation in XOMA Royalty's business if the merger is completed.
• The merger is subject to stockholder approval, and failure to obtain this approval could result in the merger not being completed, potentially impacting XOMA Royalty's stock price and business.
• XOMA Royalty may be required to pay a termination fee of $40.0 million to Ligand Pharmaceuticals under certain circumstances if the merger agreement is terminated.

Risks

• The completion of the merger is subject to stockholder and regulatory approvals, and there is no guarantee these will be obtained or that closing conditions will be satisfied.
• If the merger is not completed, XOMA Royalty's business may be adversely affected, and it may need to raise additional capital.
• The pendency of the merger may divert management's attention and resources from ongoing business operations.
• XOMA Royalty stockholders who wish to exercise dissenters rights under Nevada law must strictly comply with specific procedures, including not voting in favor of the merger.
• The tax consequences of the merger are complex, and the tax treatment of the CVRs is uncertain, potentially leading to tax liability without corresponding cash distribution.
• The Janssen Litigation is complex and may take many years to resolve, with no assurance of a favorable outcome or any recovery.
• The CVRs are not transferable and will not be listed on any exchange, meaning there will be no market for them.

Future Outlook

The merger is expected to be completed in the third quarter of 2026, subject to stockholder and regulatory approvals. Post-merger, XOMA Royalty will cease to be an independent public company, and its common stock will be delisted from Nasdaq.

Management Comments

• "We look forward to the successful completion of the Merger and the Holding Company Reorganization."
• The XOMA Royalty Board of Directors recommends that XOMA Royalty stockholders vote FOR each of the proposals to be considered at the Special Meeting.

Industry Context

StockSavvy.ai notes that this transaction aligns with the trend of consolidation within the royalty aggregator and biopharmaceutical financing sectors, where companies seek scale and diversification. Ligand Pharmaceuticals, as a leading royalty aggregator, is expanding its portfolio through this acquisition.

Comparison to Industry Standards

• The $39.00 per share cash consideration represents a premium of approximately 29% to XOMA Royalty's closing share price on March 25, 2026.
• The premium is also approximately 68% over the closing share price on February 11, 2026, prior to the public disclosure of the Janssen Litigation.
• The offer represents a 23% premium to XOMA Royalty's 60-day volume-weighted average share price and a 41% premium to its 90-day volume-weighted average share price as of April 24, 2026.

Legal Proceedings

• XOMA Royalty alleges breach of contract and unjust enrichment against Janssen Biotech, Inc. for alleged unauthorized use of its Bacterial Cell Expression Technology (BCE Technology) in the development and commercialization of Tremfya (guselkumab).

Stakeholder Impact

• XOMA Royalty stockholders will receive cash and CVRs, with the CVRs' value dependent on the Janssen Litigation outcome.
• Employees may experience uncertainty regarding their roles post-merger, and the company may face challenges in retaining key personnel.
• Milestone and royalty partners, licensees, and suppliers may be impacted by the change in ownership and corporate structure.

Next Steps

• XOMA Royalty stockholders will vote on the merger agreement and related proposals at a special meeting.
• Regulatory approvals, including HSR Act clearance, must be obtained.
• The parties will work to complete the merger, expected in the third quarter of 2026.

Key Dates

Recommendation

The $39.00 cash component provides a solid floor, but the significant uncertainty surrounding the CVRs and the potential for the Janssen Litigation to yield no recovery warrants a cautious approach. While the premium is attractive, the contingent nature of a portion of the deal consideration and the inherent risks associated with the litigation make a 'hold' recommendation appropriate for existing shareholders, while new investors might consider the cash component as a baseline with speculative upside from the CVR.

Keywords

XOMA Royalty Corporation, Ligand Pharmaceuticals Incorporated, Merger Agreement, Holding Company Reorganization, Contingent Value Rights, CVR, Janssen Litigation, Special Meeting, Stockholder Vote, SEC Filing, Form S-4, Proxy Statement